FIELD: chemistry.
SUBSTANCE: invention relates to EP4 receptor antagonist, which is a tricyclic spiro compound of general formula (I), or a pharmaceutically acceptable salt thereof, as well as to a pharmaceutical composition containing such a compound as an active ingredient, that is having EP4 receptor antagonist activity, for preventing and/or treating diseases caused by EP4 receptor activation.
EFFECT: disclosed is a tricyclic spiro compound.
20 cl, 1 dwg, 2 tbl, 142 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION CONTAINING EP4 ANTAGONIST AND IMMUNE CONTROL POINT INHIBITOR | 2017 |
|
RU2748731C2 |
| BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOHUANIDINE COMPOUNDS, USEFUL FOR THE TREATMENT OF PAIN | 2013 |
|
RU2664541C2 |
| MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS THROMBIN INHIBITORS | 2011 |
|
RU2639876C2 |
| SPIRO CONDENSED DERIVATIVES OF 2,3-DIHYDROINDOLE, THEIR USE IN OPHTHALMOLOGY | 2017 |
|
RU2712039C2 |
| ANTIVIRAL SUBSTRATE ISOSTER ESTERS OF ASPARTATE PROTEASE OR THEIR SALTS, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL PREPARATION AND COMPOSITION | 1995 |
|
RU2164229C2 |
| SUBSTITUTED CHROMANS | 2015 |
|
RU2718060C2 |
| SPIRO CONDENSED PYRROLIDINE DERIVATIVES AS INHIBITORS OF DEUBIQUITINATING ENZYMES (DUB) | 2017 |
|
RU2730552C2 |
| PHENYL DERIVATIVES | 2012 |
|
RU2619105C2 |
| PROTEIN TYROSIN PHOSPHATASE INHIBITORS | 2020 |
|
RU2799449C2 |
| N-(2-CYANO HETEROCYCLYL)PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | 2014 |
|
RU2669922C2 |
